POINT BIOPHARMA GLOBAL INC (PNT) Fundamental Analysis & Valuation

NASDAQ:PNT • US7305411099

12.5 USD
+0.02 (+0.16%)
At close: Dec 26, 2023
12.51 USD
+0.01 (+0.08%)
After Hours: 12/26/2023, 8:10:43 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This PNT fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

5

Taking everything into account, PNT scores 5 out of 10 in our fundamental rating. PNT was compared to 520 industry peers in the Biotechnology industry. While PNT has a great health rating, its profitability is only average at the moment. PNT is not valued too expensively and it also shows a decent growth rate.


Dividend Valuation Growth Profitability Health

4

1. PNT Profitability Analysis

1.1 Basic Checks

  • In the past year PNT was profitable.
  • PNT had a positive operating cash flow in the past year.
PNT Yearly Net Income VS EBIT VS OCF VS FCFPNT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 0 50M -50M 100M 150M

1.2 Ratios

  • The Return On Assets of PNT (20.22%) is better than 99.49% of its industry peers.
  • PNT has a Return On Equity of 22.77%. This is amongst the best in the industry. PNT outperforms 97.81% of its industry peers.
  • With an excellent Return On Invested Capital value of 18.63%, PNT belongs to the best of the industry, outperforming 99.33% of the companies in the same industry.
Industry RankSector Rank
ROA 20.22%
ROE 22.77%
ROIC 18.63%
ROA(3y)-20.26%
ROA(5y)N/A
ROE(3y)-32.35%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
PNT Yearly ROA, ROE, ROICPNT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 0 20 -20 -40 -60 -80

1.3 Margins

  • PNT has a better Profit Margin (39.62%) than 99.33% of its industry peers.
  • PNT's Operating Margin of 44.22% is amongst the best of the industry. PNT outperforms 98.99% of its industry peers.
Industry RankSector Rank
OM 44.22%
PM (TTM) 39.62%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PNT Yearly Profit, Operating, Gross MarginsPNT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 10 20 30 40 50

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. PNT Health Analysis

2.1 Basic Checks

  • PNT has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
  • PNT has more shares outstanding than it did 1 year ago.
  • PNT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
PNT Yearly Shares OutstandingPNT Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 20M 40M 60M 80M 100M
PNT Yearly Total Debt VS Total AssetsPNT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 100M 200M 300M 400M 500M

2.2 Solvency

  • PNT has an Altman-Z score of 16.90. This indicates that PNT is financially healthy and has little risk of bankruptcy at the moment.
  • PNT has a Altman-Z score of 16.90. This is amongst the best in the industry. PNT outperforms 91.23% of its industry peers.
  • PNT has a debt to FCF ratio of 0.06. This is a very positive value and a sign of high solvency as it would only need 0.06 years to pay back of all of its debts.
  • With an excellent Debt to FCF ratio value of 0.06, PNT belongs to the best of the industry, outperforming 97.30% of the companies in the same industry.
  • A Debt/Equity ratio of 0.01 indicates that PNT is not too dependend on debt financing.
  • PNT's Debt to Equity ratio of 0.01 is in line compared to the rest of the industry. PNT outperforms 43.17% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF 0.06
Altman-Z 16.9
ROIC/WACC1.67
WACC11.15%
PNT Yearly LT Debt VS Equity VS FCFPNT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 0 100M 200M 300M 400M

2.3 Liquidity

  • PNT has a Current Ratio of 9.13. This indicates that PNT is financially healthy and has no problem in meeting its short term obligations.
  • PNT has a Current ratio of 9.13. This is in the better half of the industry: PNT outperforms 73.52% of its industry peers.
  • A Quick Ratio of 9.13 indicates that PNT has no problem at all paying its short term obligations.
  • Looking at the Quick ratio, with a value of 9.13, PNT is in the better half of the industry, outperforming 73.69% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 9.13
Quick Ratio 9.13
PNT Yearly Current Assets VS Current LiabilitesPNT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 100M 200M 300M 400M 500M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. PNT Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 195.40% over the past year.
EPS 1Y (TTM)195.4%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%11.54%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 22.94% on average over the next years. This is a very strong growth
  • The Revenue is expected to grow by 72.58% on average over the next years. This is a very strong growth
EPS Next Y9.21%
EPS Next 2Y-2.62%
EPS Next 3Y36.93%
EPS Next 5Y22.94%
Revenue Next Year-14.35%
Revenue Next 2Y21.4%
Revenue Next 3Y112.36%
Revenue Next 5Y72.58%

3.3 Evolution

PNT Yearly Revenue VS EstimatesPNT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 200M 400M 600M
PNT Yearly EPS VS EstimatesPNT Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 0.5 -0.5 1 -1 1.5

More info and screens

Find the best growth stocksShow best growing peers

5

4. PNT Valuation Analysis

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 15.06 indicates a correct valuation of PNT.
  • Compared to the rest of the industry, the Price/Earnings ratio of PNT indicates a rather cheap valuation: PNT is cheaper than 97.47% of the companies listed in the same industry.
  • PNT is valuated rather cheaply when we compare the Price/Earnings ratio to 27.03, which is the current average of the S&P500 Index.
  • PNT is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE 15.06
Fwd PE N/A
PNT Price Earnings VS Forward Price EarningsPNT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, PNT is valued cheaply inside the industry as 97.98% of the companies are valued more expensively.
  • Based on the Price/Free Cash Flow ratio, PNT is valued cheaply inside the industry as 97.64% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 14.37
EV/EBITDA 6.16
PNT Per share dataPNT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 3

4.3 Compensation for Growth

  • The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
  • A more expensive valuation may be justified as PNT's earnings are expected to grow with 36.93% in the coming years.
PEG (NY)1.64
PEG (5Y)N/A
EPS Next 2Y-2.62%
EPS Next 3Y36.93%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. PNT Dividend Analysis

5.1 Amount

  • No dividends for PNT!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

PNT Fundamentals: All Metrics, Ratios and Statistics

POINT BIOPHARMA GLOBAL INC

NASDAQ:PNT (12/26/2023, 8:10:43 PM)

After market: 12.51 +0.01 (+0.08%)

12.5

+0.02 (+0.16%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13
Earnings (Next)03-22
Inst Owners0.74%
Inst Owner Change0%
Ins Owners5.11%
Ins Owner Change0%
Market Cap1.33B
Revenue(TTM)243.80M
Net Income(TTM)96.60M
Analysts69.33
Price Target15.05 (20.4%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)21.81%
Min EPS beat(2)19.08%
Max EPS beat(2)24.55%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)312.79%
Min Revenue beat(2)211.88%
Max Revenue beat(2)413.69%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)2.12%
EPS NQ rev (1m)0%
EPS NQ rev (3m)14.94%
EPS NY rev (1m)0%
EPS NY rev (3m)12.19%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)83.86%
Revenue NY rev (1m)0%
Revenue NY rev (3m)25.31%
Valuation
Industry RankSector Rank
PE 15.06
Fwd PE N/A
P/S 5.46
P/FCF 14.37
P/OCF 11.89
P/B 3.14
P/tB 3.14
EV/EBITDA 6.16
EPS(TTM)0.83
EY6.64%
EPS(NY)-1.04
Fwd EYN/A
FCF(TTM)0.87
FCFY6.96%
OCF(TTM)1.05
OCFY8.41%
SpS2.29
BVpS3.98
TBVpS3.98
PEG (NY)1.64
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA 20.22%
ROE 22.77%
ROCE 24.56%
ROIC 18.63%
ROICexc 81.93%
ROICexgc 81.93%
OM 44.22%
PM (TTM) 39.62%
GM N/A
FCFM 38.02%
ROA(3y)-20.26%
ROA(5y)N/A
ROE(3y)-32.35%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.51
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF 0.06
Debt/EBITDA 0.04
Cap/Depr 742.31%
Cap/Sales 7.92%
Interest Coverage 250
Cash Conversion 101.45%
Profit Quality 95.96%
Current Ratio 9.13
Quick Ratio 9.13
Altman-Z 16.9
F-Score6
WACC11.15%
ROIC/WACC1.67
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)195.4%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%11.54%
EPS Next Y9.21%
EPS Next 2Y-2.62%
EPS Next 3Y36.93%
EPS Next 5Y22.94%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-14.35%
Revenue Next 2Y21.4%
Revenue Next 3Y112.36%
Revenue Next 5Y72.58%
EBIT growth 1Y234.92%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-34.05%
EBIT Next 3Y38.92%
EBIT Next 5Y-10.32%
FCF growth 1Y261.67%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y371.58%
OCF growth 3YN/A
OCF growth 5YN/A

POINT BIOPHARMA GLOBAL INC / PNT FAQ

What is the ChartMill fundamental rating of POINT BIOPHARMA GLOBAL INC (PNT) stock?

ChartMill assigns a fundamental rating of 5 / 10 to PNT.


Can you provide the valuation status for POINT BIOPHARMA GLOBAL INC?

ChartMill assigns a valuation rating of 5 / 10 to POINT BIOPHARMA GLOBAL INC (PNT). This can be considered as Fairly Valued.


What is the profitability of PNT stock?

POINT BIOPHARMA GLOBAL INC (PNT) has a profitability rating of 4 / 10.


What is the financial health of POINT BIOPHARMA GLOBAL INC (PNT) stock?

The financial health rating of POINT BIOPHARMA GLOBAL INC (PNT) is 8 / 10.